Picture of Hanmi Pharm logo

128940 — Hanmi Pharm News Story

0.000.00%
kr flag iconLast trade - 00:00
HealthcareSpeculativeLarge CapHigh Flyer

S.Korea's biopharmaceutical shares fall on dimmer outlook

** Celltrion  068270.KS  and Samsung Biologics  207940.KS ,
South Korea's top biopharmaceutical companies, drop on Monday
after Goldman Sachs forecast deepening competition in the
bioindustry
    ** Celltrion and Samsung Biologics lose more than 3 pct
each, while Hanmi Pharm  128940.KS  tumbles 6.3 pct
    ** Goldman Sachs cuts Celltrion's target price to 147,000
won ($129.50). Its previous close was 272,000 won. In a report,
the investment bank says competition will come from growing
Chinese and Indian firms
    ** Following the report, Samsung Biologics halted its
week-long winning streak boosted by Samsung Group's investment
plan
    ** The broader KOSPI market  .KS11  was down 1.5 pct as of
0336 GMT, as the Turkish crisis spreads 
   ($1 = 1,135.1000 won)

 ((Reuters Messaging:
hayoung.choi.thomsonreuters.com@reuters.net))

Recent news on Hanmi Pharm

See all news